Excitatory and inhibitory neurotransmission is chronically altered following perinatal NMDA receptor blockade

European Neuropsychopharmacology

Volumn 19, Issue 4, 2009, Pages 256-265

  du Bois, Teresa Marie ^a,b   Deng, Chao ^a,b   Han, Mei ^a,b   Newell, Kelly Anne ^a,b   Huang, Xu Feng ^a,b  

^a SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Brain development; GABAA receptor; NMDA receptor; Phencyclidine; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; DIZOCILPINE; MUSCIMOL; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; BRAIN REGION; CINGULATE GYRUS; COGNITION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; GABAERGIC TRANSMISSION; HIPPOCAMPUS; MALE; NEUROTRANSMISSION; NONHUMAN; PERINATAL PERIOD; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; THALAMUS;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; BRAIN; BRAIN MAPPING; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GABA AGONISTS; MALE; MUSCIMOL; PHENCYCLIDINE; PREGNANCY; PROTEIN BINDING; RATS; RECEPTORS, GABA; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 60749102883     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.12.002     Document Type: Article

References (62)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney Jr. W.E., and Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52 (1995) 258-266
2. Andersen J.D., and Pouzet B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of d-serine. Neuropsychopharmacology 29 (2004) 1080-1090
3. Beasley C.L., and Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 24 (1997) 349-355
4. Behar T.N., Scott C.A., Greene C.L., Wen X., Smith S.V., Maric D., Liu Q.-Y., Colton C.A., and Barker J.L. Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J. Neurosci. 19 (1999) 4449-4461
5. Benes F.M., McSparren J., Bird E.D., SanGiovanni J.P., and Vincent S.L. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch. Gen. Psychiatry 48 (1991) 996-1001
6. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J. Neurosci. 12 (1992) 924-929
7. A receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75 (1996) 1021-1031
8. Benes F.M., Kwok E.W., Vincent S.L., and Todtenkopf M.S. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry 44 (1998) 88-97
9. Brickman A.M., Buchsbaum M.S., Shihabuddin L., Byne W., Newmark R.E., Brand J., Ahmed S., Mitelman S.A., and Hazlett E.A. Thalamus size and outcome in schizophrenia. Schizophr. Res. 71 (2004) 473-484
10. Casey D.E., Daniel D.G., Wassef A.A., Tracy K.A., Wozniak P., and Sommerville K.W. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 28 (2003) 182-192
11. Clinton S.M., Haroutunian V., and Meador-Woodruff J.H. Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia. J. Neurochem. 98 (2006) 1114-1125
12. Coyle J.T., and Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology 174 (2004) 32-38
13. Dean B., Scarr E., Bradbury R., and Copolov D. Decreased hippocampal (CA3) NMDA receptors in schizophrenia. Synapse 32 (1999) 67-69
14. A receptors in the superior temporal gyrus in schizophrenia. Exp. Brain Res. 168 (2006) 587-590
15. du Bois T., Hsu C.-W., Li Y., Tan Y., Deng C., and Huang X.-F. Altered dopamine receptor and dopamine transporter binding and tyrosine hydroxylase mRNA expression following perinatal NMDA receptor blockade. Neurochem. Res. 33 (2008) 1224-1231
16. du Bois T.M., Huang X.-F., and Deng C. Perinatal administration of PCP alters adult behaviour in female Sprague-Dawley rats. Behav. Brain Res. 188 (2008) 416-419
17. Dursun S.M., and Deakin J.F. Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study. J. Psychopharmacology 15 (2001) 297-301
18. Facchinetti F., Ciani E., Dall'Olio R., Virgili M., Contestabile A., and Fonnum F. Structural, neurochemical and behavioural consequences of neonatal blockade of NMDA receptor through chronic treatment with CGP 39551 or MK-801. Dev. Brain Res. 74 (1993) 219-224
19. Fredriksson A., Archer T., Alm H., Gordh T., and Eriksson P. Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration. Behav. Brain Res. 153 (2004) 367-376
20. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., Uzunov D., and Costa E. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch.Gen. Psychiatry 57 (2000) 1061-1069
21. Haberny K.A., Paule M.G., Scallet A.C., Sistare F.D., Lester D.S., Hanig J.P., and Slikker Jr. W. Ontogeny of the N-methyl-d-aspartate (NMDA) receptor system and susceptibility to neurotoxicity. Toxicol. Sci. 68 (2002) 9-17
22. Hansen H.H., Briem T., Dzietko M., Sifringer M., Voss A., Rzeski W., Zdzisinska B., Thor F., Heumann R., and Stepulak A. Mechanisms leading to disseminated apoptosis following NMDA receptor blockade in the developing rat brain. Neurobiol. Dis. 16 (2004) 440-453
23. Harris L.W., Sharp T., Gartlon J., Jones D.N., and Harrison P.J. Long-term behavioural, molecular and morphological effects of neonatal NMDA receptor antagonism. Eur. J. Neurosci. 18 (2003) 1706-1710
24. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Tenkova T.I., Stefovska V., Turski L., and Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283 (1999) 70-74
25. Insel T.R., Miller L.P., and Gelhard R.E. The ontogeny of excitatory amino acid receptors in rat forebrain-I. N-methyl-d-aspartate and quisqualate receptors. Neuroscience 35 (1990) 31-43
26. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
27. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J. Neural Transm. 77 (1989) 231-236
28. Lane H.-Y., Huang C.-L., Wu P.-L., Liu Y.-C., Chang Y.-C., Lin P.-Y., Chen P.-W., and Tsai G. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia. Biol. Psychiatry 60 (2006) 645-649
29. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., and Grace A.A. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci. 31 (2008) 234-242
30. Lodge D.J., and Grace A.A. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J. Neurosci. 27 (2007) 11424-11430
31. Lodge D., Behrens M., and Grace A. A loss of parvalbumin containing interneurons is associated with diminished gamma oscillatory activity in an animal model of schizophrenia. Schizophr. Res. 102 (2008) 112-112
32. McDonald J.W., and Johnston M.V. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res. Rev. 15 (1990) 41-70
33. Mitani A., Watanabe M., and Kataoka K. Functional change of NMDA receptors related to enhancement of susceptibility to neurotoxicity in the developing pontine nucleus. J. Neurosci. 18 (1998) 7941-7952
34. 3H]MK-801 binding sites in neonate rat brain. Brain Res. 487 (1989) 376-379
35. Newell K.A., Zavitsanou K., and Huang X.-F. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. Neuroreport 16 (2005) 1363-1367
36. Newell K.A., Zavitsanou K., Jew S.K., and Huang X.-F. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 31 (2007) 225-233
37. Nudmamud S., and Reynolds G.P. Increased density of glutamate/N-methyl-d-aspartate receptors in superior temporal cortex in schizophrenia. Neurosci. Lett. 304 (2001) 9-12
38. O'Donnell P., Lewis B.L., Weinberger D.R., and Lipska B.K. Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cereb. Cortex 12 (2002) 975-982
39. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., and Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat. Med. 13 (2007) 1102-1107
40. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press Inc., London
41. Pearce I.A., Cambray-Deakin M.A., and Burgoyne R.D. Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells. FEBS Lett. 223 (1987) 143-147
42. Reynolds G.P., Beasley C.L., and Zhang Z.J. Understanding the neurotransmitter pathology of schizophrenia: selective deficits of subtypes of cortical GABAergic neurons. J. Neural Transm. 109 (2002) 881-889
43. Ritter L.M., Unis A.S., and Meador-Woodruff J.H. Ontogeny of ionotropic glutamate receptor expression in human fetal brain. Dev. Brain Res. 127 (2001) 123-133
44. Ritter L.M., Vazquez D.M., and Meador-Woodruff J.H. Ontogeny of ionotropic glutamate receptor subunit expression in the rat hippocampus. Dev. Brain Res. 139 (2002) 227-236
45. Sircar R. Postnatal phencyclidine-induced deficit in adult water maze performance is associated with N-methyl-d-aspartate receptor upregulation. Int. J. Dev. Neurosci. 21 (2003) 159-167
46. Sircar R., and Soliman K.F.A. Effects of postnatal PCP treatment on locomotor behavior and striatal D2 receptor. Pharmacol. Biochem. Behav. 74 (2003) 943-952
47. Stefani M.R., and Moghaddam B. Transient N-methyl-d-aspartate receptor blockade in early development causes lasting cognitive deficits relevant to schizophrenia. Biol. Psychiatry 57 (2005) 433-436
48. Tiihonen J., Hallikainen T., Ryynanen O.P., Repo-Tiihonen E., Kotilainen I., Eronen M., Toivonen P., Wahlbeck K., and Putkonen A. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol. Psychiatry 54 (2003) 1241-1248
49. Tsai G., Lane H.-Y., Yang P., Chong M.-Y., and Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry 55 (2004) 452-456
50. 2 dopamine receptors recruit a GABA component for their attenuation of excitatory synaptic transmission in the adult rat prefrontal cortex. Synapse 61 (2007) 843-850
51. Tyszkiewicz J.P., Gu Z., Wang X., Cai X., and Yan Z. Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex. J. Physiol. 554 (2004) 765-777
52. Volk D.W., Austin M.C., Pierri J.N., Sampson A.R., and Lewis D.A. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 57 (2000) 237-245
53. Wang C., and Johnson K.M. Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J. Neurosci. Res. 81 (2005) 284-292
54. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., and Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107 (2001) 535-550
55. Wang C., McInnis J., West J.B., Bao J., Anastasio N., Guidry J.A., Ye Y., Salvemini D., and Johnson K.M. Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by M40403, a superoxide dismutase mimetic. J. Pharmacol. Exp. Ther. 304 (2003) 266-271
56. Wang C., Fridley J., and Johnson K.M. The role of NMDA receptor upregulation in phencyclidine-induced cortical apoptosis in organotypic culture. Biochem. Pharmacol. 69 (2005) 1373-1383
57. Wang C., Yang S.F., Xia Y., and Johnson K.M. Postnatal phencyclidine administration selectively reduces adult cortical parvalbumin-containing interneurons. Neuropsychopharmacology 33 (2008) 2442-2456
58. Wassef A.A., Dott S.G., Harris A., Brown A., O'Boyle M., Meyer III W.J., and Rose R.M. Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J. Clin. Psychopharmacol. 20 (2000) 357-361
59. Wiley J.L., Buhler K.G., Lavecchia K.L., and Johnson K.M. Pharmacological challenge reveals long-term effects of perinatal phencyclidine on delayed spatial alternation in rats. Prog. Neuro-psychopharmacol. Biol. Psychiatry 27 (2003) 867-873
60. Wilson M.A., Kinsman S.L., and Johnston M.V. Expression of NMDA receptor subunit mRNA after MK-801 treatment in neonatal rats. Dev. Brain Res. 109 (1998) 211-220
61. Xia Y., and Haddad G.G. Ontogeny and distribution of GABAA receptors in rat brainstem and rostral brain regions. Neuroscience 49 (1992) 973-989
62. Zavitsanou K., Ward P.B., and Huang X.F. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 27 (2002) 826-833